REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPSMarket Beat·2 days ago, 10:56 PMRGNX-496.00%
REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% UpsideTradingView·Aug 6 at 06:20 PMRGNX-496.00%
Regenxbio Q2 FY26 swings to net income of $22.71 million; revenue climbs to $108.02 millionPUBT·Aug 6 at 06:21 AMRGNX-496.00%ABBV+89.00%
Regenxbio | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 108.02 MEarnings Watch·Aug 6 at 06:16 AMRGNX-496.00%
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Aug 4 at 01:29 AMRGNX-496.00%
Regenxbio schedules conference call to discuss second-quarter results and operational updatePUBT·Aug 3 at 06:05 AMRGNX-496.00%
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights | RGNX Stock NewsStockTitan·Aug 2 at 10:05 PMRGNX-496.00%
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmPR Newswire·Jul 21 at 06:29 PMRGNX-496.00%
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Whybenzinga_article·Jul 21 at 02:52 PMRGNX-496.00%ADCT0.00%
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatmentsbenzinga_article·Jul 20 at 09:45 AMRGNX-496.00%
REGENXB priced $9.00 IPO of 10.0M shares plus 1.11M pre-funded warrants, raising ~$107.8M netTradingView·Jul 20 at 06:43 AMRGNX-496.00%
